Semaglutide for the treatment of obesity
Author:
Funder
National Institute of Nursing Research
National Institutes of Health
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference60 articles.
1. World Health Organization. Obesity and overweight 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
2. Obesity and cardiovascular disease;Ortega;Circ Res,2016
3. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes;NEJM,2013
4. Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States;Aggarwal;Prog Cardiovasc Dis,2021
5. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus;Koliaki;Diabetes Ther,2011
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Agonist) Therapy;American Journal of Roentgenology;2024-09-04
2. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019;Metabolism;2024-09
3. In vivo Antibody Painting for Next Generation Weight Loss Drugs;2024-08-23
4. Weighing your options—intragastric balloon versus semaglutide;Surgical Endoscopy;2024-08-13
5. Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance;Medicine;2024-08-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3